GEMAYEL GEORGES
SEC CIK 1256088 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | Dir | 27.3K | — | $2.35M | 14 | 2022-02-19 | 2026-03-06 |
Most active insiders at SUPN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Khattar Jack A. | Pres, CEO, Dir | — | $7.72M |
| 2 | Bhatt Padmanabh P. | CSO, SVP of IP | — | $5.42M |
| 3 | NEWHALL CHARLES W III | Dir | — | $1.27M |
| 4 | Mottola Frank | SVP, Chief Tech. Ops. Off | — | $1.10M |
| 5 | GEMAYEL GEORGES | Dir | — | $1.00M |
| 6 | Horich William Todd | SVP, Commercial Ops | — | $483.8K |
| 7 | Hudson Frederick M. | Dir | — | $271.7K |
| 8 | Sensenig Bethany | Dir | — | $228.3K |
| 9 | Rubin Jonathan | SVP, Chief Medical Off | — | — |
| 10 | Barlow Carrolee | Dir | — | — |
Transactions 14
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-09 | 2026-03-05+ | SUPN | SUPERNUS PHARMACEUTICALS, INC. | GEMAYEL GEORGES | Dir | S - Sale+OE | $53.38 | -18.8K | 27.3K | -41% | -$1.00M |
| D | 2026-03-09 | 2026-03-06 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | GEMAYEL GEORGES | Dir | M - OptEx | $25.30 | +7,905 | 36.1K | +28% | +$200.0K |
| D | 2026-02-25 | 2026-02-23 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | GEMAYEL GEORGES | Dir | M - OptEx | $12.98 | +15.0K | 33.7K | +80% | +$194.7K |
| D | 2026-02-25 | 2026-02-24 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | GEMAYEL GEORGES | Dir | A - Grant | $0.00 | +4,475 | 38.2K | +13% | $0 |
| D | 2025-02-24 | 2025-02-22 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | GEMAYEL GEORGES | Dir | A - Grant | $0.00 | +5,369 | 18.7K | +40% | $0 |
| D | 2024-11-12 | 2024-11-08 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | GEMAYEL GEORGES | Dir | M - OptEx | $11.46 | +10.8K | 24.1K | +81% | +$123.6K |
| D | 2024-11-12 | 2024-11-08 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | GEMAYEL GEORGES | Dir | S - Sale+OE | $36.30 | -10.8K | 13.3K | -45% | -$391.6K |
| D | 2024-11-08 | 2024-11-07 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | GEMAYEL GEORGES | Dir | M - OptEx | $11.46 | +14.2K | 27.5K | +107% | +$162.9K |
| D | 2024-11-08 | 2024-11-07 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | GEMAYEL GEORGES | Dir | S - Sale+OE | $36.62 | -14.2K | 13.3K | -52% | -$520.5K |
| DM | 2024-09-17 | 2024-09-13 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | GEMAYEL GEORGES | Dir | S - Sale+OE | $31.33 | -13.9K | 13.3K | -51% | -$435.0K |
| D | 2024-09-17 | 2024-09-13 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | GEMAYEL GEORGES | Dir | M - OptEx | $11.46 | +10.0K | 23.3K | +75% | +$114.6K |
| D | 2024-02-27 | 2024-02-23 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | GEMAYEL GEORGES | Dir | A - Grant | $0.00 | +3,886 | 17.2K | +29% | $0 |
| D | 2023-02-24 | 2023-02-22 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | GEMAYEL GEORGES | Dir | A - Grant | $0.00 | +3,882 | 13.3K | +41% | $0 |
| D | 2022-02-23 | 2022-02-19 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | GEMAYEL GEORGES | Dir | A - Grant | $0.00 | +4,222 | 9,433 | +81% | $0 |
Purchase Sale Sale after option exercise All abbreviations